Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials (Q44029291)

29 November 2017

0 references

Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials (English)

1 reference

29 November 2017

phase III clinical trial

0 references

1 reference

1 reference

Qing Ye

1

1 reference

PubMed ID

23543268

29 November 2017

Hong-Lin Chen

series ordinal

2

1 reference

29 November 2017

31 March 2013

1 reference

Archives of Gynecology and Obstetrics

29 November 2017

1 reference

29 November 2017

288

1 reference

29 November 2017

3

1 reference

29 November 2017

655-666

1 reference

https://scigraph.springernature.com/pub.10.1007/s00404-013-2820-1

29 November 2017

0 references

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

21 January 2018

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

Recent progress in the diagnosis and treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

Understanding and managing the possible adverse effects associated with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00404-013-2820-1

10.1007/S00404-013-2820-1

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference

PubMed ID

23543268